Headshot of Megan Ehret & Raymond Love

Photo: Megan Ehret, PharmD, MS, BCPP, and Raymond Love, PharmD, BCPP, FASHP


Nearly a decade in the making, University of Maryland, Baltimore pharmacy and medical experts were instrumental in a groundbreaking vote in November to remove a longstanding barrier to patients being prescribed clozapine, a medication used to treat schizophrenia and schizoaffective disorder.

A joint U.S. Food and Drug Administration (FDA) advisory committee — the Drug Safety and Risk Management Advisory Committee and the Psychopharmacologic Drugs Advisory Committee — voted overwhelmingly on Nov. 19 to eliminate the risk evaluation and mitigation strategy (REMS) program for clozapine.

Read the full story on the School of Pharmacy's News Center. 

Students, faculty, and staff, let your voice be heard!
Submit Your Story.